Autoimmune factor XIII deficiency with unusual laboratory and clinical phenotype.

autoimmune disease blood coagulation factor XIII factor XIII deficiency hemorrhagic disorder

Journal

Journal of thrombosis and haemostasis : JTH
ISSN: 1538-7836
Titre abrégé: J Thromb Haemost
Pays: England
ID NLM: 101170508

Informations de publication

Date de publication:
06 2020
Historique:
received: 17 03 2020
accepted: 19 03 2020
pubmed: 21 4 2020
medline: 15 5 2021
entrez: 21 4 2020
Statut: ppublish

Résumé

Hemorrhagic diathesis due to anti-factor XIII (FXIII) autoantibody is a rare but severe disorder. Challenges of the diagnosis and treatment is demonstrated by the case of a 67-year-old female without previous bleeding history, who suffered a huge muscular hematoma. Without blank subtraction 18% plasma FXIII activity was measured; however, after correction for blank the activity was below the limit of detection and the lack of fibrin cross-linking in the patient's plasma confirmed the latter result. FXIII-A

Identifiants

pubmed: 32311817
doi: 10.1111/jth.14811
pii: S1538-7836(22)01438-6
doi:

Substances chimiques

Factor XIII 9013-56-3
Factor XIIIa EC 2.3.2.13

Types de publication

Case Reports Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

1330-1334

Informations de copyright

© 2020 The Authors. Journal of Thrombosis and Haemostasis published by Wiley Periodicals LLC on behalf of International Society on Thrombosis and Haemostasis.

Références

Muszbek L, Bereczky Z, Bagoly Z, Komaromi I, Katona E. Factor XIII: a coagulation factor with multiple plasmatic and cellular functions. Physiol Rev. 2011;91:931-972.
Mitchell JL, Mutch NJ. Let's cross-link: diverse functions of the promiscuous cellular transglutaminase factor XIII-A. J Thromb Haemost. 2019;17:19-30.
Muszbek L, Bagoly Z, Cairo A, Peyvandi F. Novel aspects of factor XIII deficiency. Curr Opin Hematol. 2011;18:366-372.
Dorgalaleh A, Naderi M, Hosseini MS, et al. Factor XIII deficiency in Iran: a comprehensive review of the literature. Semin Thromb Hemost. 2015;41:323-329.
Franchini M, Frattini F, Crestani S, Bonfanti C. Acquired FXIII inhibitors: a systematic review. J Thromb Thrombolysis. 2013;36:109-114.
Muszbek L, Penzes K, Katona E. Auto- and alloantibodies against factor XIII: laboratory diagnosis and clinical consequences. J Thromb Haemost. 2018;16:822-832.
Verbruggen B, Novakova I, Wessels H, Boezeman J, van den Berg M, Mauser-Bunschoten E. The Nijmegen modification of the Bethesda assay for factor VIII: C inhibitors: improved specificity and reliability. Thromb Haemost. 1995;73:247-251.
Menegatti M, Palla R, Boscarino M, et al. Minimal factor XIII activity level to prevent major spontaneous bleeds. J Thromb Haemost. 2017;15:1728-1736.
Karpati L, Penke B, Katona E, Balogh I, Vamosi G, Muszbek L. A modified, optimized kinetic photometric assay for the determination of blood coagulation factor XIII activity in plasma. Clin Chem. 2000;46:1946-1955.
Katona E, Haramura G, Karpati L, Fachet J, Muszbek L. A simple, quick one-step ELISA assay for the determination of complex plasma factor XIII (A2B2). Thromb Haemost. 2000;83:268-273.
Katona E, Ajzner E, Toth K, Karpati L, Muszbek L. Enzyme-linked immunosorbent assay for the determination of blood coagulation factor XIII A-subunit in plasma and in cell lysates. J Immunol Methods. 2001;258:127-135.
Tang N, Li D, Wang X, Yang J. Concurrent hematoma and venous thrombosis in a patient with autoimmune acquired factor XIII deficiency. Int J Lab Hematol. 2020;42:e4-e6.
Ogawa Y, Yanagisawa K, Souri M, et al. Successful management of a patient with autoimmune hemorrhaphilia due to anti-factor XIII/13 antibodies complicated by pulmonary thromboembolism. Acta Haematol. 2017;137:141-147.
Boehlen F, Casini A, Chizzolini C, et al. Acquired factor XIII deficiency: a therapeutic challenge. Thromb Haemost. 2013;109:479-487.
Miesbach W. Rituximab in the treatment of factor XIII inhibitor possibly caused by Ciprofloxacin. Thromb Haemost. 2005;93:1001-1003.

Auteurs

Julien Bovet (J)

Hemophilia Care Center University Hospital of Dijon, Dijon, France.

Boglárka Hurják (B)

Division of Clinical Laboratory Science, Department of Laboratory Medicine, Faculty of Medicine, University of Debrecen, Debrecen, Hungary.
Kálmán Laki Doctoral School of Biomedical and Clinical Sciences, University of Debrecen, Debrecen, Hungary.

Emmanuel De Maistre (E)

Hemophilia Care Center University Hospital of Dijon, Dijon, France.

Éva Katona (É)

Division of Clinical Laboratory Science, Department of Laboratory Medicine, Faculty of Medicine, University of Debrecen, Debrecen, Hungary.

Krisztina Pénzes (K)

Division of Clinical Laboratory Science, Department of Laboratory Medicine, Faculty of Medicine, University of Debrecen, Debrecen, Hungary.

László Muszbek (L)

Division of Clinical Laboratory Science, Department of Laboratory Medicine, Faculty of Medicine, University of Debrecen, Debrecen, Hungary.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH